Serious Infections in Offspring Exposed in Utero to Vedolizumab

Jonah H Gorodensky; Sasha Bernatsky; Waqqas Afif; Yvan St-Pierre; Kristian B Filion; Évelyne Vinet

doi:10.1093/ibd/izad079

Serious Infections in Offspring Exposed in Utero to Vedolizumab

Inflamm Bowel Dis. 2024 Mar 1;30(3):496-498. doi: 10.1093/ibd/izad079.

Authors

Jonah H Gorodensky^{1

2}, Sasha Bernatsky^{1

2

3}, Waqqas Afif^{2

3}, Yvan St-Pierre², Kristian B Filion^{1

4}, Évelyne Vinet^{1

2

3}

Affiliations

¹ Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
² Research Institute of the McGill University Health Center, McGill University, Montreal, Quebec, Canada.
³ Department of Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada.
⁴ Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

No abstract available

Keywords: TNFi; immunosuppressants; pregnancy outcomes; serious infections; tumor necrosis factor inhibitors; vedolizumab.

Plain language summary

Controlling IBD during pregnancy is important for maternal and fetal outcomes. We created a cohort of children born to mothers with IBD, comparing the risk of infections in those exposed to vedolizumab vs unexposed. We detected no increased risk.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Humans
Infections*
Prenatal Exposure Delayed Effects*

Substances

Antibodies, Monoclonal, Humanized
vedolizumab

Plain language summary

Publication types

MeSH terms

Substances

Grants and funding